Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]